Brief: Calytrix Bio Enters An Agreement To Be Acquired By Lilly
BRIEF-Calytrix Bio Enters An Agreement To Be Acquired By Lilly Nov 16 (Reuters) - Eli Lilly and Company LLY.N:
CALYTRIX BIO ENTERS AN AGREEMENT TO BE ACQUIRED BY LILLY TO ADVANCE OUTCOMES FOR PATIENTS LIVING WITH ESSENTIAL THROMBOCYTHEMIA AND MYELOFIBROSIS
CALYTRIX BIO: LILLY WILL ACQUIRE CALYTRIX, AND CALYTRIX SHAREHOLDERS COULD RECEIVE UP TO $1.5 BILLION IN CASH
Source text: ID:nPn61YGnna
Further company coverage: LLY.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eli Lilly and
See all newsBiogen's anti-tau Alzheimer's drug benefits increase at 2 years
Eli Lilly’s $1.4 trln valuation is heavy with hope
Lilly signs cancer research deal with Stipple Bio worth up to $5.9 billion (updated)
Brief: Stipple Bio Enters Multi-Target Oncology Collaboration With Eli Lilly
Deals of the day-Mergers and acquisitions